# US 2010/0063094 A1 · Methods for treatment of colorectal cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063094 A1
- Document ID: US20100063094A1
- Status: Published application
- Kind: A1
- Application number: 12/621,038
- Filed: 2009-11-18
- Published: 2010-03-11
- Earliest claimed: 2002-05-17
- Assignees: Celgene Corporation
- Inventors: Jerome B. Zeldis
- Web page: https://patentgrep.com/patent/US20100063094A1

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/425: Thiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/515: Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A method of treating colorectal cancer, which comprises administering to a patient having colorectal cancer about 5 to about 50 mg per day of a compound of the formula:
or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein the colorectal cancer is Dukes C & D colorectal cancer, unresectable colorectal carcinoma, refractory colorectal cancer, relapsed colorectal cancer, or metastatic colorectal cancer.

### Claim 24 (depends on 22)

The method of claim 22, wherein the compound is

### Claim 25 (depends on 22)

The method of claim 22, wherein the compound is a pharmaceutically acceptable salt.

### Claim 26 (depends on 22)

The method of claim 22, wherein the compound is a pharmaceutically acceptable solvate.

### Claim 27 (depends on 22)

The method of claim 22, wherein the compound is a pharmaceutically acceptable stereoisomer.

### Claim 28 (depends on 27)

The method of claim 27, wherein the stereoisomer is an enantiomerically pure R isomer.

### Claim 29 (depends on 27)

The method of claim 27, wherein the stereoisomer is an enantiomerically pure S isomer.

### Claim 30 (depends on 22)

The method of claim 22, which further comprises administering a therapeutically effective amount of a second active agent.

### Claim 31 (depends on 30)

The method of claim 30, wherein the second active agent is hematopoietic growth factor, a cytokine, or an anti-cancer agent.

### Claim 32 (depends on 30)

The method of claim 30, wherein the second active agent is capecitabine, fluorouracil, leucovorin, irinotecan, xeloda, or a combination thereof.

### Claim 33 (depends on 30)

The method of claim 30, wherein the second active agent is capecitabine, xeloda, irinotecan, or a combination thereof.

### Claim 34 (depends on 30)

The method of claim 30, wherein the second active agent is capecitabine.

### Claim 35 (depends on 30)

The method of claim 30, wherein the second active agent is fluorouracil, leucovorin, irinotecan, or a combination thereof.

### Claim 36 (depends on 22)

The method of claim 22, which further comprises administering radiation therapy, hormonal therapy, biological therapy or immunotherapy.

### Claim 37 (depends on 22)

The method of claim 22, wherein the colorectal cancer is relapsed, refractory or resistant to conventional therapy.

### Claim 38 (depends on 22)

The method of claim 22, wherein the compound is administered orally.

### Claim 39 (depends on 38)

The method of claim 38, wherein the compound is administered in the form of a capsule or tablet.

### Claim 40 (depends on 22)

The method of claim 22, wherein the compound is administered in an amount of from about 10 to about 25 mg per day.

### Claim 41 (depends on 22)

The method of claim 22, wherein the compound is administered in an amount of about 5, 10, 20, 25, 30, or 50 mg per day.

### Claim 42 (depends on 22)

The method of claim 22, wherein the compound is administered in an amount of from about 5 mg per day to about 25 mg per day.

### Claim 43 (depends on 22)

The method of claim 22, wherein the compound is administered in an amount of about 25 mg per day.

### Claim 44 (depends on 22)

The method of claim 22, wherein the compound is administered cyclically.

### Claim 45 (depends on 44)

The method of claim 44, wherein one cycle comprises four to six weeks.

### Claim 46 (depends on 44)

The method of claim 44, wherein one cycle comprises the administration of the compound for 21 days followed by seven days rest.

### Claim 47 (depends on 44)

The method of claim 44, wherein the compound is administered for four to twenty-four weeks with one to six weeks of rest.

### Claim 48 (depends on 22)

The method of claim 22, wherein the compound is administered in an amount of from about 5 to about 25 mg per day for 21 days every 28 days for sixteen to twenty-four weeks.

### Claim 49 (depends on 44)

The method of claim 44, wherein the compound is administered in an amount of about 25 mg per day for 21 days followed by seven days rest in a 28 day cycle.

### Claim 50 (depends on 22)

The method of claim 22, wherein the compound is administered in an amount of about 5 mg per day.

### Claim 51 (depends on 22)

The method of claim 22, wherein the compound is administered in an amount of 10 mg per day.

### Claim 52 (depends on 22)

The method of claim 22, wherein the compound is administered in an amount of 15 mg per day.

### Claim 53 (depends on 22)

The method of claim 22, wherein the compound is administered in a capsule of 5 mg, 10 mg, 15 mg or 25 mg.

### Claim 54 (depends on 39)

The method of claim 39, wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
